Neboglamine

2023-06-28: Nootropics reference: https://beta.nootropicswiki.org/details/neboglamine

Neboglamine (Nebostinel) (CR22-49, XY-2401) #

• The only known NMDAR glycine site PAM, enhancing the binding of D-Serine.
  • Specifically, it’s selective for NR2A.
  • According to sirsad, oral D-Serine causing molecular-level oxidative stress could be due to it ending up in extrasynaptic regions it doesn’t normally exist in.
• NR3 agonist, which unfortunately is anti-cognitive. That’s why noname thinks it inhibits PFC function.
• CR 2249: a new putative memory enhancer. Behavioural studies on learning and memory in rats and mice (1996)
• Cognition Enhancing Profile of CR 2249, a New NMDA-Glycine Site Modulator
• Antipsychotic-like effects of the N-methyl-D-aspartate receptor modulator neboglamine: an immunohistochemical and behavioural study in the rat.
• Novel NMDA Receptor Modulators: An Update

• Characterization of a novel putative cognition enhancer mediating facilitation of glycine effect on strychnine-resistant sites coupled to NMDA receptor complex #

• See also apimostinel (NRX-1074) (sold on TeamLTR) and rapastinel (GLYX-13), modulators that bind to unique domains independent of the glycine site!!!
  • Positive N-Methyl-D-Aspartate Receptor Modulation by Rapastinel Promotes Rapid and Sustained Antidepressant-Like Effects
• There is also NYX-2925 (aka AGN-241751) and NYX-458.
• (It’s not an antagonist but apimostinel could be? There’s a biphasic dose response.) GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects
• Weak selective Noradrenaline reuptake inhibitor at high doses (104.5μM/L, 10x that of being a glycine site PAM)
  • Also has an NRI metabolite.

Supplementation #

• 30, 50, 100mg? Phase one clinical trials chose 200mg, and this dose prevents ischemia.
  • Sirsad says 50>200mg, and maybe 20mg intranasal.
• Sir’s initial impressions were that it lasts ~3 hours and then longer lasting for the rest of the day.